Attached files
| file | filename |
|---|---|
| EX-10.78 - EXHIBIT 10.78 - Arbutus Biopharma Corp | exhibit1078lizhowardea.htm |
| EX-10.79 - EXHIBIT 10.79 - Arbutus Biopharma Corp | exhibit1079monsantoamendme.htm |
| EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corp | exhibit311.htm |
| EX-23.1 - EXHIBIT 23.1 - Arbutus Biopharma Corp | exhibit231kpmgconsent.htm |
| EX-10.81 - EXHIBIT 10.81 - Arbutus Biopharma Corp | exhibit1081monsantoamendme.htm |
| EX-21.1 - EXHIBIT 21.1 - Arbutus Biopharma Corp | exhibit211listingofsubsidi.htm |
| EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corp | exhibit312.htm |
| EX-10.80 - EXHIBIT 10.80 - Arbutus Biopharma Corp | exhibit1080monsantoamendme.htm |
| EX-32.2 - EXHIBIT 32.2 - Arbutus Biopharma Corp | exhibit322.htm |
| 10-K - 10-K 2015 - Arbutus Biopharma Corp | arbutus10k2015.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Arbutus Biopharma Corporation (the “Company”) on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Mark J. Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company. |
Date: March 9, 2016
/s/ Mark J. Murray | |||
Name: | Mark J. Murray | ||
Title: | President and Chief Executive Officer | ||